About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- Human, premenopausal women with HSDD, n=31, randomised double-blind placebo-controlled crossover design
- Sample size
- 31
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
Small sample (n=31); single study of this design; mechanistic/neuroimaging endpoint rather than the clinical desire/distress endpoints of the pivotal Phase 3 trials.
Cited in
Neuroimaging in 31 women
PT-141 (Bremelanotide) · Research finding
Limited
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.